Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Receivables (2021 - 2023)

Inhibikase Therapeutics (IKT) has 3 years of Receivables data on record, last reported at $79604.0 in Q2 2023.

  • On a quarterly basis, Receivables rose 1114.96% to $79604.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $79604.0, a 1114.96% increase, with the full-year FY2022 number at $39881.0, down 63.79% from a year prior.
  • Receivables reached $79604.0 in Q2 2023 per IKT's latest filing, up from $64521.0 in the prior quarter.
  • Over the last five years, Receivables for IKT hit a ceiling of $110141.0 in Q4 2021 and a floor of $6552.0 in Q2 2022.
  • A 3-year average of $51788.1 and a median of $47976.0 in 2022 define the central range for Receivables.
  • Peak YoY movement for Receivables: crashed 63.79% in 2022, then surged 1114.96% in 2023.
  • Tracing IKT's Receivables over 3 years: stood at $110141.0 in 2021, then plummeted by 63.79% to $39881.0 in 2022, then skyrocketed by 99.6% to $79604.0 in 2023.
  • Business Quant data shows Receivables for IKT at $79604.0 in Q2 2023, $64521.0 in Q1 2023, and $39881.0 in Q4 2022.